A growing body of evidence pinpoints neuroinflammation as a pivotal factor driving brain-related pathogenesis. Yet, a crucial question lingers: among the various immune cell groups residing within the brain, which one orchestrates this inflammatory reaction?
List view / Grid view
The University of Alabama at Birmingham
UAB researchers have found that adding TBX20 to the reprogramming cocktail MGT 133 promoted cardiac reprograming.
A new study led by the Indiana University School of Medicine showed human induced pluripotent stem cells can improve visual acuity, vascular health and other complications related to type 2 diabetes.
The self-assembling, nanomatrix gel may represent the first effective therapy to promote healthy arteriovenous fistula (AVF) maturation in kidney disease patients.
Limiting neuroinflammation was shown to be a promising approach to treat neurological diseases such as stroke and spinal cord injury in mice.
A team of researchers have reversed lung fibrosis in a mouse model, highlighting a new therapeutic target for pulmonary fibrosis.
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
A new study has shown that restoring the amount of the kinase, HIPK2, in a kinase-depleted mouse model rescued it from heart failure and identifies HIPK2 as a novel regulator of heart failure progression.
Researchers in the U.S. have identified a new link between epigenetic changes in the brains of rats and resulting translational control during fear memory reconsolidation.
Congestive heart failure is a terminal disease that affects nearly 6 million people in the U.S.; yet its management is limited to symptomatic treatments as its causal mechanisms – including its most common form, ischemic cardiomyopathy – are unknown.